Skip to main content

Year: 2022

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

— Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the third quarter ended September 30, 2022. “This quarter, we continued to make robust progress across our 3 clinical programs,” said Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer. “The FDA granted Fast Track Designation to Lomecel-BTM for infants with Hypoplastic...

Continue reading

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly participating in the ACROBAT Advance Long-term Extension Study SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) —  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2022. “This has been yet another successful quarter of executing our strategy to build a leading endocrinology company by advancing our clinical pipeline of internally discovered drug candidates and preparing to add to that pipeline with our highly productive drug discovery efforts. Progress includes completion of enrollment in the Phase 3 PATHFNDR-1...

Continue reading

Form 8.3 – [REACH PLC 11 11 2022] CGAML (formerly HHL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED –formerly HARGREAVE HALE LIMITED(for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree REACH PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Form 8.3 – [EMIS GROUP PLC 11 11 2022] – CGWL

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree EMIS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2022, and recent business highlights. Recent HighlightsProgress Continued for IMPAHCT Global Phase 2b/Phase 3 Clinical Trial Presented IMPAHCT at CHEST Expanded Intellectual Property Portfolio Management Team StrengthenedProgress Continued for IMPAHCT Global Phase 2b/Phase 3 Clinical Trial. IMPAHCT (Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial) is a Phase 2b/Phase 3 trial of AV-101, our dry powder inhaled formulation of the anti-proliferative drug imatinib for the treatment of pulmonary arterial...

Continue reading

Magic Software Reports Third Quarter 2022 Financial Results with Record Breaking Revenues of $144 Million, Reflecting a 19% Year-Over-Year Growth. Net income reached a record-breaking $11.5 Million, Reflecting 53% Year-Over-Year Growth

Operating income for the third quarter increased by 34% year-over-year to a record-breaking result of $16.1 million; Non-GAAP operating income for the third quarter increased by 14% year-over-year to a third quarter record-breaking result of $18.5 million OR YEHUDA, Israel, Nov. 14, 2022 (GLOBE NEWSWIRE) — Magic Software Enterprises Ltd. (Nasdaq and TASE: MGIC), a global provider of IT consulting services and end-to-end integration and application development platforms solutions, announced today its financial results for the third quarter ended September 30, 2022. Summary Results for the Third Quarter 2022 (USD in millions, except per share data)    GAAP           Non-GAAP            Q3 2022     Q3 2021     % Change     Q3 2022     Q3 2021     % Change  Revenues   $ 144.0     $ 120.9       19.1 %   $ 144.0     $ 120.9       19.1 %Gross...

Continue reading

Tower Semiconductor Reports Third Quarter 2022 Record Revenue of $427 Million

Sequential increases in profitability, resulting in 16.2% net margins, exceeding the second half 2022 target MIGDAL HAEMEK, Israel, Nov. 14, 2022 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the third quarter ended September 30, 2022. Third Quarter of 2022 Results Overview Revenue for the third quarter of 2022 was $427 million, as compared to $387 million in the third quarter of 2021, reflecting 10% revenue growth. Organic revenue grew by 22% year over year for the third quarter of 2022 (organic revenue defined as total revenue excluding revenues from (i) Nuvoton in the Japanese fabs and (ii) Maxim in the San Antonio fab). Revenue for the second quarter of 2022 was $426 million. Gross profit for the third quarter of 2022 was $125 million, 46% higher than $85 million recorded...

Continue reading

Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights

Libmeldy® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe First case of MLD confirmed from newborn screening study provides critical evidence to advance adoption of universal screening in key countries Clinical Type B meeting with U.S. FDA to take place in early 2023 prior to OTL-200 BLA submission First neurocognitive data from OTL-201 POC trial in MPS-IIIA selected for oral presentation at 64th American Society of Hematology Annual Meeting & Exposition Ended Q3 with $146.6M of cash and investments and runway now into the second quarter of 2024 BOSTON and LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced recent business highlights along with its financial results for the quarter ended September...

Continue reading

D-BOX Technologies Reports Second Quarter 2023 Results

Strong order book for back half of yearTotal revenues increased 10% to $6.1 million compared to the same quarter last year Rights for use, rental and maintenance revenues surged 38% year-over-year to $1.8 million July was D-BOX’s second-best month ever in terms of number of tickets sold on a global basis Fifth consecutive quarter of positive adjusted EBITDA* Net loss amounted to $0.7 million compared to $0.4 million in the second quarter of 2022MONTREAL, Nov. 14, 2022 (GLOBE NEWSWIRE) — D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO) a world leader in haptic and immersive experiences, announced today financial results for the second quarter of fiscal 2023 ended September 30, 2022. All dollar amounts are expressed in Canadian currency. “Fiscal 2023 is shaping up to be a strong year for D-BOX,”...

Continue reading

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Initiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds worldwide rights to CLN-619, from 54% to 92% Continued enrollment in CLN-049 and CLN-619 clinical studies with initial clinical data updates on track for mid-2023 Cash and investments of approximately $607 million as of September 30, 2022 CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) a biopharmaceutical company focused on modality-agnostic targeted oncology, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2022. “We continued to execute across our programs through the third quarter and will deliver multiple important milestones in 2023,” said Nadim Ahmed, Chief Executive Officer of Cullinan...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.